Free Rhodium (II) citrate and rhodium (II) citrate magnetic carriers as potential strategies for breast cancer therapy

Journal of Nanobiotechnology

Volumn 9, Issue , 2011, Pages

  Carneiro, Marcella L B ^a   Nunes, Eloiza S ^b   Peixoto, Raphael C A ^a   Oliveira, Ricardo G S ^a   Lourenço, Luiza H M ^a   da Silva, Izabel C R ^a   Simioni, Andreza R ^c   Tedesco, Antônio C ^c   de Souza, Aparecido R ^b   Lacava, Zulmira G M ^a   Báo, Sônia N ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN FILAMENT; ANTI-TUMORS; BREAST CANCER; BREAST CARCINOMA CELLS; CELL LINES; CYTOSTATIC ACTIVITIES; CYTOTOXIC; CYTOTOXIC EFFECTS; DELIVERY SYSTEMS; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; MAGHEMITE NANOPARTICLE; MAGNETIC CARRIERS; MAGNETIC NANOPARTICLES; MAGNETOLIPOSOMES; MEMBRANE BLEBBING; MORPHOLOGICAL ALTERATION; NUCLEAR FRAGMENTATION; PHOSPHATIDYLSERINE; POTENTIAL TOOL; SUPERPARAMAGNETIC PARTICLES; TUMOR CELLS;

CARBOXYLATION; CELL CULTURE; CELL DEATH; CHEMOTHERAPY; CYTOTOXICITY; DRUG DELIVERY; IRON ORES; IRON OXIDES; NANOMAGNETICS; NANOPARTICLES; PROTEINS; SUPERPARAMAGNETISM; TUMORS;

RHODIUM;

FERRIC OXIDE; LIPOSOME; MAGNETOLIPOSOME; PACLITAXEL; PHOSPHATIDYLSERINE; RHODIUM CITRATE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MAGNETITE NANOPARTICLE; RHODIUM;

ACTIN FILAMENT; ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL VACUOLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOCHONDRION; MOUSE; NONHUMAN; ANIMAL; BREAST; BREAST TUMOR; CARCINOMA; CELL LINE; DRUG DELIVERY SYSTEM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; PATHOLOGY; UDDER; ULTRASTRUCTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST; BREAST NEOPLASMS; CARCINOMA; CELL LINE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; MAGNETITE NANOPARTICLES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MICE; RHODIUM;

EID: 79953086684     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/1477-3155-9-11     Document Type: Article

References (50)

1. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009, 33:315-318. 10.1016/j.canep.2009.10.003, 19896917.
2. Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov 2006, 1:1-22. 10.2174/157489206775246458, 18221023.
3. Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol 2003, 7:481-489. 10.1016/S1367-5931(03)00081-4, 12941423.
4. Katsaros N, Anagnostopoulou A. Rhodium and its compounds as potential agents in cancer treatment. Crit Rev Oncol Hematol 2002, 42:297-308. 10.1016/S1040-8428(01)00222-0, 12050021.
5. Junicke H, Hart JR, Kisko J, Glebov O, Kirsch IR, Barton JK. A rhodium (III) complex for high-affinity DNA base-pair mismatch recognition. Proc Natl Acad Sci USA 2003, 100:3737-3742. 10.1073/pnas.0537194100, 152991, 12610209.
6. Angeles-Boza AM, Chifotides HT, Aguirre JD, Chouai A, Fu PK, Dunbar KR, Turro C. Dirhodium(II, II) complexes: molecular characteristics that affect in vitro activity. J Med Chem 2006, 49:6841-6847. 10.1021/jm060592h, 17154514.
7. Zyngier S, Kimura E, Najjar R. Antitumor effects of rhodium (II) citrate in mice bearing Ehrlich tumors. Braz J Med Biol Res 1989, 22:397-401.
8. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021. 10.1016/j.biomaterials.2004.10.012, 15626447.
9. Namdeo M, Saxena S, Tankhiwale R, Bajpai M, Mohan YM, Bajpai SK. Magnetic nanoparticles for drug delivery applications. J Nanosci Nanotechnol 2008, 8:3247-3271. 10.1166/jnn.2008.399, 19051873.
10. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284. 10.1016/S0168-3659(99)00248-5, 10699287.
11. Asadishad B, Vossoughi M, Alamzadeh I. In vitro release behavior and cytotoxicity of doxorubicin-loaded gold nanoparticles in cancerous cells. Biotechnol Lett 2010, 32:649-654. 10.1007/s10529-010-0208-x, 20131082.
12. Kohler N, Sun C, Wang J, Zhang M. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 2005, 21:8858-8864. 10.1021/la0503451, 16142971.
13. Dreaden EC, Mwakwari SC, Sodji QH, Oyelere AK, El-Sayed MA. Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment. Bioconjug Chem 2009, 20:2247-2253. 10.1021/bc9002212, 2839930, 19919059.
14. Ma G, Yang J, Zhang L, Song C. Effective antitumor activity of paclitaxel-loaded poly (varepsilon-caprolactone)/pluronic F68 nanoparticles after intratumoral delivery into the murine breast cancer model. Anticancer Drugs 21:261-269. 10.1097/CAD.0b013e32833410a2, 20016371.
15. Kettering M, Zorn H, Bremer-Streck S, Oehring H, Zeisberger M, Bergemann C, Hergt R, Halbhuber KJ, Kaiser WA, Hilger I. Characterization of iron oxide nanoparticles adsorbed with cisplatin for biomedical applications. Phys Med Biol 2009, 54:5109-5121. 10.1088/0031-9155/54/17/003, 19661569.
16. Douziech-Eyrolles L, Marchais H, Herve K, Munnier E, Souce M, Linassier C, Dubois P, Chourpa I. Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine 2007, 2:541-550. 2676819, 18203422.
17. Sun YK, Ma M, Zhang Y, Gu N. Synthesis of nanometer-size maghemita particles from magnetite. Colloids and Surfaces A: Physicochemical and Engineering Aspects 2004, 245:15-19.
18. International Center of Diffraction Data. PDF Card 22-1086 2000,
19. Batlle X, Labarta A. Finite-size effects in fine particles: magnetic and transport properties. Journal of Physics D: Applied Physics 2002, 35:,:15-42.
20. Lu AH, Salabas EL, Schuth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angewandte Chemie 2007, 46:1222-1244. 10.1002/anie.200602866, 17278160.
21. Bellamy LJ. The Infrared Spectra of Complex Molecules. 1975, Chapman and Hall, 3.
22. Drmota A, Kosak A, Znidarsic A. A mechanism for the adsorption of carboxylic acids onto the surface of magnetic nanoparticles. Materials and Technology 2008, 42:79-83.
23. Boyar EB, Robinson SD. Rhodium(II) Carboxylates. Coordination Chemistry Reviews 1983, 50:109-208.
24. Deng YF, Jiang YQ, Hong QM, Zhou ZH. Speciation of water-soluble titanium citrate: Synthesis, structural, spectroscopic properties and biological relevance. Polyhedron 2007, 26:1561-1569.
25. Zhou ZH, Hou SY, Cao ZX, Tsai KR, Chow YL. Syntheses, spectroscopies and structures of molybdenum(VI) complexes with homocitrate. Inorganic Chemistry 2006, 45:8447-8451. 10.1021/ic061429f, 16999446.
26. Najjar R, Santos FS, Seidel W. Synthesis and characterization of the rhodium(II) citrate complex. Anais da Academia Brasileira de Ciências 1987, 59:1-2.
27. Liu ZL, Wang HB, Lu QH, Du GH, Peng L, Du YQ, Zhang SM, Yao KL. Synthesis and characterization of ultrafine well-dispersed magnetic nanoparticles. Journal of Magnetism and Magnetic Materials 2004, 283:248-262.
28. Simioni AR, Pelisson MM, Beltrame M, Tedesco AC. Photophysical and photobiological studies of a silicon tribenzonaphthoporphyrazinato incorporated into liposomes for photodynamic therapy use. J Nanosci Nanotechnol 2008, 8:3208-3215. 10.1166/jnn.2008.108, 18681070.
29. de Souza AR, Najjar R, Glikmanas S, Zyngier SB. Water-soluble rhodium(II) carboxylate adducts: cytotoxicity of the new compounds. J Inorg Biochem 1996, 64:1-5. 10.1016/0162-0134(95)00227-8, 8837497.
30. Howard RA, Kimball AP, Bear JL. Mechanism of action of tetra-mu-carboxylatodirhodium(II) in L1210 tumor suspension culture. Cancer Res 1979, 39:2568-2573.
31. de Souza AR, Coelho EP, Zyngier SB. Comparison of the anti-neoplastic effects of dirhodium(II) tetrapropionate and its adducts with nicotinate and isonicotinate anions in mice bearing Ehrlich tumors. Eur J Med Chem 2006, 41:1214-1216. 10.1016/j.ejmech.2006.05.016, 16822594.
32. Chifotides HT, Dunbar KR. Interactions of metal-metal-bonded antitumor active complexes with DNA fragments and DNA. Acc Chem Res 2005, 38:146-156. 10.1021/ar0302078, 15709734.
33. Gottlieb E, Armour SM, Harris MH, Thompson CB. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ 2003, 10:709-717. 10.1038/sj.cdd.4401231, 12761579.
34. Mizushima N. Methods for monitoring autophagy. Int J Biochem Cell Biol 2004, 36:2491-2502. 10.1016/j.biocel.2004.02.005, 15325587.
35. Turcotte S, Giaccia AJ. Targeting cancer cells through autophagy for anticancer therapy. Curr Opin Cell Biol 22:246-251. 10.1016/j.ceb.2009.12.007, 20056398.
36. Alberti C. Cytoskeleton structure and dynamic behaviour: quick excursus from basic molecular mechanisms to some implications in cancer chemotherapy. Eur Rev Med Pharmacol Sci 2009, 13:13-21.
37. Rosenblum MD, Shivers RR. 'Rings' of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere. Comp Biochem Physiol C Toxicol Pharmacol 2000, 125:121-131.
38. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998, 10:123-130. 10.1016/S0955-0674(98)80095-1, 9484604.
39. Kwok JC, Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation?. Crit Rev Oncol Hematol 2002, 42:65-78. 10.1016/S1040-8428(01)00213-X, 11923069.
40. Petri-Fink A, Chastellain M, Juillerat-Jeanneret L, Ferrari A, Hofmann H. Development of functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. Biomaterials 2005, 26:2685-2694. 10.1016/j.biomaterials.2004.07.023, 15585272.
41. Sinisterra RD, Shastri VP, Najjar R, Langer R. Encapsulation and release of rhodium(II) citrate and its association complex with hydroxypropyl-beta-cyclodextrin from biodegradable polymer microspheres. J Pharm Sci 1999, 88:574-576. 10.1021/js9804314, 10229652.
42. Burgos AE, Belchior JC, Sinisterra RD. Controlled release of rhodium (II) carboxylates and their association complexes with cyclodextrins from hydroxyapatite matrix. Biomaterials 2002, 23:2519-2526. 10.1016/S0142-9612(01)00386-6, 12033599.
43. Lacava ZGM, Azevedo RB, Martins EV, Lavava LM, Freitas MLL, Garcia VAP. Biological effect of magnetic fluids: toxicity studies. Journal of magnetism and magnetic materials 1999, 201:431-434.
44. Morais PC, Santos RL, Pimenta ACM, B AR, D LEC. Preparation and characterization of ultra-stable biocompatible magnetic fluids using citrate-coated cobalt ferrite nanoparticles. Thin solid films 2006, 515:266-270.
45. de Freitas ER, Soares PR, Santos Rde P, dos Santos RL, da Silva JR, Porfirio EP, Bao SN, Lima EC, Morais PC, Guillo LA. In vitro biological activities of anionic gamma-Fe2O3 nanoparticles on human melanoma cells. J Nanosci Nanotechnol 2008, 8:2385-2391. 10.1166/jnn.2008.275, 18572653.
46. Sahu SK, Mallick SK, Santra S, Maiti TK, Ghosh SK, Pramanik P. In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery. J Mater Sci Mater Med 2010, 5:1587-97.
47. Bear JL, Gray HB, Rainen L, Chang IM, Howard R, Serio G, Kimball AP. Interaction of Rhodium(II) carboxylates with molecules of biologic importance. Cancer Chemother Rep 1975, 59:611-620.
48. Jeffery GH, Basset J, Mendham J, Denney RC. VOGEL's Textbook of quantitative chemical analysis. 1989, New York: Longman Scientific & Technical, 5.
49. Kang YS, Risbud S, Rabolt JF, Stroeve P. Synthesis and characterizations of nanometer-size Fe3O4 and g-Fe2O3 particles. Chemistry of Materials 1996, 8:2209-2211.
50. Ralston E, Blumenthal R, Weinstein JN, Sharrow SO, Henkart P. Lysophosphatidylcholine in liposomal membranes. Enhanced permeability but little effect on transfer of a water-soluble fluorescent marker into human lymphocytes. Biochimica et Biophysica Acta (BBA) - Biomembranes 1980, 597:543-551.